Campanale Antonella, Ventimiglia Marco, Alfò Marco, Cipriani Marta, Minella Daniela, Lispi Lucia, Iachino Achille
Directorate General of Medical Devices and Pharmaceutical service, Italian Ministry of Health, Via Ribotta 5, 00144, Rome, Italy.
Department of Statistical Sciences, Sapienza University of Rome, Rome, Italy.
Aesthetic Plast Surg. 2025 Mar;49(5):1304-1313. doi: 10.1007/s00266-024-04426-y. Epub 2024 Oct 14.
Accurate estimation of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) incidence is crucial for assessing breast-implant-associated risk. However, the size of the implanted population worldwide is unknown, making it challenging to appropriately estimate this figure. This study aims to provide a new reliable and reproducible method to estimate the breast-implanted-population (BIP), reporting a reliable annual BIA-ALCL incidence estimate. Moreover, we discuss all activities performed over the past decade in collecting complete histories, managing, and monitoring outcomes of each Italian case.
Data from the National Breast Implant Registry and from manufacturers have been used to define a new formula to estimate the BIP at risk of developing a breast-implant-related event. From the BIA-ALCL registry, complete information on Italian cases has been collected and analysed. Overall survival is estimated by the Kaplan-Meier curve.
From 2010 to June 2024, 111 BIA-ALCL cases were recorded in Italy. The estimated incidence rate showed an upward trend, ranging from 2.68 to 6.35 cases per 100,000 patient-years. Thanks to newly promoted disease awareness, most patients had a complete response to treatment, resulting in a three-year overall survival rate estimate of 98.2%.
The BIP formula showed to be an innovative, effective and reproducible tool to make a reliable estimation of the implanted population, confirming that BIA-ALCL is a rare disease with an incidence rate estimate varying from 2.7 to 6.3 cases/100.000 patient-years in the last five years. Eleven-year experience in this field also confirmed that this disease has a favorable prognosis if properly treated.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
准确估计乳房植入物相关间变性大细胞淋巴瘤(BIA-ALCL)的发病率对于评估乳房植入物相关风险至关重要。然而,全球植入人群的规模尚不清楚,这使得准确估计这一数字具有挑战性。本研究旨在提供一种新的可靠且可重复的方法来估计乳房植入人群(BIP),报告可靠的BIA-ALCL年发病率估计值。此外,我们讨论了过去十年中在收集完整病史、管理和监测每例意大利病例结局方面所开展的所有活动。
来自国家乳房植入物登记处和制造商的数据已被用于定义一个新公式,以估计有发生乳房植入物相关事件风险的BIP。从BIA-ALCL登记处收集并分析了意大利病例的完整信息。通过Kaplan-Meier曲线估计总生存率。
2010年至2024年6月,意大利共记录了111例BIA-ALCL病例。估计发病率呈上升趋势,每100,000患者年为2.68至6.35例。由于最近疾病认知度的提高,大多数患者对治疗有完全反应,三年总生存率估计为98.2%。
BIP公式是一种创新、有效且可重复的工具,可用于可靠估计植入人群,证实BIA-ALCL是一种罕见疾病,过去五年发病率估计为每100,000患者年2.7至6.3例。该领域的十一年经验还证实,如果得到妥善治疗,这种疾病预后良好。
证据水平III:本刊要求作者为每篇文章指定证据水平。有关这些循证医学评级的完整描述,请参阅目录或作者在线指南www.springer.com/00266 。